Diarrhea, Unspecified Adult Solid Tumor, Protocol Specific
Conditions
Keywords
Quality of Life
Brief summary
This randomized phase II clinical trial studies probiotic supplementation in preventing treatment-related diarrhea in patients with cancer undergoing chemotherapy. Probiotics may help prevent diarrhea caused by treatment with chemotherapy.
Detailed description
PRIMARY OBJECTIVES: I. Incidence of moderate/severe (grade 2-4) diarrhea graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. II. Functional Assessment of Chronic Illness Therapy - Diarrhea (FACIT-D) Trial Outcome Index. SECONDARY OBJECTIVES: I. To evaluate the effects of probiotic supplementation on dose delays or reductions due to gastrointestinal (GI) toxicity. II. To evaluate the effects of probiotic supplementation on anti-diarrheal medication use. III. To evaluate the effects of probiotic supplementation on overall health-related quality of life (HR-QOL). IV. To evaluate the effects of probiotic supplementation on febrile neutropenia. V. To evaluate the effects of probiotic supplementation on adverse GI effects. VI. To evaluate the effects of probiotic supplementation on overall survival. VII. To evaluate the effects of probiotic supplementation on progression free survival. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive a mixture of Lactobacillus plantarum strain 299v, Bifidobacterium lactis probiotic supplement, and Lactobacillus acidophilus probiotic orally (PO) twice daily (BID) for 9 weeks. Treatment continues in the absence of unacceptable toxicity. ARM II: Patients receive placebo PO BID 9 weeks. Treatment continues in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up at 4 weeks and then every 3 months.
Interventions
DIETARY_SUPPLEMENTLactobacillus plantarum strain 299v
Given PO
DIETARY_SUPPLEMENTLactobacillus acidophilus probiotic
Given PO
DIETARY_SUPPLEMENTplacebo
Given PO
OTHERlaboratory biomarker analysis
Correlative studies
OTHERquestionnaire administration
Ancillary studies
PROCEDUREquality-of-life assessment
Ancillary studies
DIETARY_SUPPLEMENTBifidobacterium lactis probiotic supplement
Given PO
Sponsors
National Cancer Institute (NCI)
Stanford University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Any patient with a documented malignancy initiating treatment including (as a single agent or in combination with other drugs) any one of the following cancer therapeutics: o Fluorouracil (5FU), capecitabine, irinotecan, paclitaxel, docetaxel, cabazitaxel, crizotinib, sorafenib, sunitinib, erlotinib, or lapatinib * Any pathologically confirmed malignancy for which the patient would receive any of the listed cancer therapeutics * Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 * Patient must have an estimated life expectancy of at least 6 months * Absolute neutrophil count (ANC) \> 1500 * Platelets \> 100K * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \< 2.5 x ULN (upper limit normal) * Serum bilirubin \< 1.5 x ULN * Serum creatinine \< 1.5 x ULN * Ability to understand and the willingness to sign a written informed consent document and comply with the treatment protocol
Exclusion criteria
* Patients currently undergoing treatment with the above listed therapeutics at time of initiation of trial; patients can have had prior treatment(s) with one or more of the agents if they are initiating a new treatment with another agent on the list, provided they have had at least a 2 week washout period * Patients currently taking anti-diarrheal medications or therapy * Patients undergoing hemodialysis * Patients with known allergic or hypersensitivity reaction to probiotics, yoghurt, or similar diet or supplemental products * Acute or chronic diarrhea, including lactose intolerance, gluten or other dietary sensitivity resulting in gastrointestinal symptoms * Pregnant or nursing patients * Known human immunodeficiency virus (HIV) positive * Prior abdominal surgery resulting in a stoma, ostomy, fistula, or other anatomic defect * Concurrent or near future radiotherapy; prior, completed radiotherapy allowed; any radiotherapy within the vicinity of the GI tract must have been completed at least 4 weeks prior to start of trial * Treatment with any investigational drug within 4 weeks prior to enrollment * Current treatment with antibiotics or other gut motility agents within 2 weeks of starting study medication * Abnormal thyroid function that is not controlled with medication * Patients taking other dietary supplements within 2 weeks of starting study medication * Any other serious or uncontrolled illness which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of grade 2-4 diarrhea over the 9-week study period, assessed by CTCAE version 4.0 | Up to 9 weeks | Will be calculated by the percentage of patients experiencing grade 2-4 diarrhea as documented by patient diary and primary oncologist's documentation. The data for patients on tyrosine kinase inhibitors and conventional cytotoxic chemotherapy will be analyzed both combined and separately. |
| FACIT-D Trial Outcome Index (TOI) | Up to 4 weeks post treatment | The FACIT-D TOI has a range of scores from 0-100 which are a combination of physical well being, functional well being, and diarrhea subscale. The data for patients on tyrosine kinase inhibitors and conventional cytotoxic chemotherapy will be analyzed both combined and separately. |
Secondary
| Measure | Time frame |
|---|---|
| Dose delays or reductions due to GI toxicity | Up to 9 weeks |
| Anti-diarrheal use | Up to 9 weeks |
| Overall HR-QOL | Up to 4 weeks post treatment |
| Febrile neutropenia | Up to 4 weeks post treatment |
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | Up to 4 weeks post treatment |
| Overall survival | Up to 2 years |
| Progression free survival | Up to 2 years |
Countries
United States
Outcome results
None listed